Illegal drug-attributable morbidity in Canada 2002

References

• World Health Organization. World health report 2002: reducing risks, promoting health life. World Health Organization, Geneva 2002
   Google Scholar
• Single E, Robson L, Xie X, Rehm J. The costs of substance abuse in Canada. Canadian Centre on Substance Abuse, Ottawa 1996
   Google Scholar
• Fischer B, Manzoni P, Rehm J. Comparing injecting and non-injecting illicit opioid users in a multi-site Canadian sample (OPICAN cohort). Eur Addict Res 2006; 12: 230–239
   PubMed Web of Science ®Google Scholar
• Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health 2006; 120: 320–328
   PubMed Web of Science ®Google Scholar
• Rehm J. Modes de consommation et répartition des drogues en Suisse. Drogues illégales en Suisse 1990 – 1993. La situation dans les cantons et en Suisse, H Fahrenkrug, J Rehm, R Müller. Seismo, Zürich 1995; 13–34
   Google Scholar
• World Health Organization. Global status report on alcohol 2004. World Health Organization, Geneva 2004
   Google Scholar
• Millson P, Challacombe L, Villeneuve P J, Fischer B, Strike C J, Myers T. Self-perceived health among Canadian opiate users: a comparison to the general population and to other chronic disease populations. Can J Public Health 2004; 95: 99–103
   PubMed Web of Science ®Google Scholar
• Bruneau J, Lamothe F, Franco E, Lachance N, Desy M, Soto J, et al. High rates of HIV infection among infection drug users participating in needle exchange programs in Montreal; results of a cohort study. Am J Epidemiol 1997; 146: 994–1002
   PubMed Web of Science ®Google Scholar
• Miller C L, Wood E, Spittal P M, Li K, Fankish J C, Braitstein P. Prevalence of incidence of HIV and hepatitis C virus coinfection among young injection drug users. J Acquir Immune Defic Syndr 2004; 36: 743–749
   PubMed Web of Science ®Google Scholar
• Ralston G E, Wilson P. Methadone programs: the costs and benefits to society and the individual. Pharmacoeconomics 1996; 10: 321–326
   PubMedGoogle Scholar
• UNAIDS: The joint united nations programme on HIV/AIDS. UNAIDS, GENEVASwitzerland 2002, Report on the Global HIV/AIDS Epidemic 2002
   Google Scholar
• Bowker S L, Soskolne C L, Houston S C, Newman S C, Jhangri G S. Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) in a Northern Alberta population. Can J Public Health 2004; 95: 188–192
   PubMed Web of Science ®Google Scholar
• Ford P M. Queen's University HIV Study Group. HIV and HEP C Seroprevalence and Associated Risk Behaviours in a Canadian Prison. HIV/AIDS Policy Law Spring 2/3, 1999; 4
   Google Scholar
• Fischer B, Medved W, Glicksman L, Rehm J. Illicit opiates in Toronto: a profile of current users. Addiction Research 1999; 7: 377–415
   Web of Science ®Google Scholar
• Millar J S. HIV, Hepatitis C, and injection drug use in British Columbia: pay now or pay later?. British Columbia Provincial Health Officer. 1998, Available from URL:http://www.healthplanning.gov.bc.ca/pho/pdf/paynow.pdf (Accessed 7 December 2003)
   Google Scholar
• Brogly S B, Bruneau J, Lamothe F, Vincelette J, Franco E L. Risk behaviour change and HIV infection among injection drug users in Montreal. AIDS 2000; 14: 2575–2582
   PubMedGoogle Scholar
• Wood E, Tyndall M W, Spittal P M, Li K, Kerr T, Hogg R S, et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?. Can Med Assoc J 2001; 165: 405–410
   PubMed Web of Science ®Google Scholar
• Golub E T, Latka M, Hagan H, Havens J T, Hudson S M, Kapadia F. Screening for depressive symptoms among HCV-infected drug users: examination of the utility of the CES-D and the Beck Depression Inventory. J Urban Health 2004; 8: 278–290
   Google Scholar
• Rettig R, Yarmolinsky A. Federal regulation of methadone treatment. National Academy Press, Washington, DC 1995
   Google Scholar
• Brienza R, Stein M, Chen M-H, Gogineni A, Sobota M, Maksad J, et al. Depression among needle exchange program and methadone maintenance clients. J Subst Abuse Treat 2000; 18: 331–337
   PubMed Web of Science ®Google Scholar
• Croughan J L, Miller J P, Wagelin D, Whitman B Y. Psychiatric illness in male and female narcotic addicts. J Clin Psychiatry 1982; 182: 225–228
   Google Scholar
• Hulse G K, English D R, Milne E, Holman C DJ. The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999; 94: 221–229
   PubMed Web of Science ®Google Scholar
• Brody S L, Slovis C M, Wrenn K D. Cocaine-related medical problems: consecutive series of 233 patients. Am J Med 1990; 88: 325–331
   PubMed Web of Science ®Google Scholar
• Fischer B, Rehm J, Blitz-Miller T. Injection drug use and preventive measures: a comparison of Canada and Western European jurisdictions over time. Can Med Assoc J 2000; 162: 1709–1713
   PubMed Web of Science ®Google Scholar
• Kemmesies U. Offene drogenszene und druckraume. Wiener Zeitschr Suchtforsch 1996; 19: 17–32
   Google Scholar
• Tobin K E, Latkin C A. The relationship between depressive symptoms and nonfatal overdose among sample of drug users in Baltimore, Maryland. J Urban Health 2003; 80: 220–229
   PubMed Web of Science ®Google Scholar
• Kantzian E J. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985; 142: 1259–1264
   PubMedGoogle Scholar
• Weiss R D, Griffin M L, Mirin S M. Drug Abuse as self-medication for depression: an empirical study. Am J Drug Alcohol Abuse 1992; 18: 121–129
   PubMed Web of Science ®Google Scholar
• Geduld J, Gatali M, Remis R S, Archibald C P. Estimates of HIV prevalence and incidence in Canada, 2002. Canadian Communicable Disease Report 2003; 29: 197–208
   PubMedGoogle Scholar
• English D, Holman C, Milne E, Winter M, Hulse G, Codde G, et al. The quantification of drug caused morbidity and mortality in Australia 1995. Commonwealth Department of Human Services and Health, CanberraAustralia 1995
   Google Scholar
• Remis R. Estimating the incidence and prevalence of hepatitis C in Canada 2002. Vancouver, BC: 2nd Canadian Conference on Hepatitis C: New Knowledge. New Hope 2004
   Google Scholar
• Roy E, Haley N, Lemire N, Boivin J, Leclerc P, Vincelette J. Hepatitis B virus infection among street youths in Montreal. Can Med Assoc J 1999; 161: 689–693
   Web of Science ®Google Scholar
• Moses S, Mestery K, Kaita K D, Minuk G Y. Viral hepatitis in a Canadian street-involved population. Can J Public Health 2002; 93: 123–128
   PubMedGoogle Scholar
• Hill A B. The environment and disease: association or causation?. Proc R Soc Med 1965; 58: 295–300
   PubMed Web of Science ®Google Scholar
• Rothman K J, Greenland S. Modern epidemiology causation and casual inference. 2nd ed. Lippincott-Raven Publishers, Philadelphia, PA 1998
   Google Scholar
• Walter S D. The estimation of interpretation of attributable risk in health research. Biometrics 1976; 32: 829–849
   PubMed Web of Science ®Google Scholar
• Walter S D. Prevention of multifactorial disease. Am J Epidemiol 1980; 112: 409–416
   PubMed Web of Science ®Google Scholar
• Millson P, Myers T, Calzavara L, Wallace E, Major C, Degani N. Regional variation in HIV prevalence and risk behaviours in Ontario injection drug users (IDU). Can J Public Health 2003; 94: 431–435
   PubMed Web of Science ®Google Scholar
• Fischer B, Rehm J, Brissette S, Brochu S, Bruneau J, el-Guebaly N, et al. Illicit opioid use in Canada: Comparing social, health and drug use characteristics of untreated users in five cities (OPICAN study). J Urban Health 2005; 82: 250–266
   PubMed Web of Science ®Google Scholar
• MacDonald S, Anglin-Bodrug K, Mann R, Erickson P, Hathaway A, Chipman M, et al. Review: Injury risk associated with cannabis and cocaine use. Drug Alcohol Depend 2003; 72: 99–115
   PubMed Web of Science ®Google Scholar
• Canadian Institute for Health Information. Discharge Abstract Database 2002. CIHI, Hospital Morbidity Database, OttawaCanada 2002, Abstracting manual
   Google Scholar
• Rice D P, Kelman S, Miller L S, Dunmeyer S. The economic cost of alcohol and drug abuse and mental illness 1985. Institute for Health and Aging, University of California, San Francisco 1990, Report No.: 90-1694
   Google Scholar
• Harwood H, Fountain D, Livermore G. The economic costs of alcohol and drug abuse in the United States, 1992. US Department of Health and Human Services, National Institutes of Health, Rockville, MD 1998
   Google Scholar
• Collins D J, Lapsley H M. Estimating the economic costs of drug abuse in Australia. Australian Government Publishing Service, Canberra 1991, Report No.: Monograph Series No. 15
   Google Scholar
• Holman C DJ, Armstrong B K. The quantification of drug caused morbidity and mortality in Australia 1988. Australian Government Publishing Service, Canberra 1990, Prepared for Department of Community Services and Health
   Google Scholar
• Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 2004; 23: 319–344
   PubMed Web of Science ®Google Scholar
• Silber B Y, Papafotiou K, Croft R J, Stough C K. An evaluation of the sensitivity of the standardised field sobreity tests to detect the presence of amphetamine. Psychopharmacology 2005; 182: 153–159
   PubMed Web of Science ®Google Scholar
• Transportation Research Board (2006) Drugs in traffic: A symposium. June, 20 – 212005. Transportation Research Board of the National Academies, Woods Hole Massachusetts, Washington, DC, Report No.: 0097-8515
   Google Scholar
• Rehm J, Baliunas D, Brochu S, Fischer B, Gnam W, Patra J, et al. The social costs of substance abuse in Canada 2002. Canadian Centre on Substance Abuse, Ottawa 2006, ISBN number 1-897321-10-4
   Google Scholar
• Statistics Canada, CANSIM. Table 051–0001. Available from: http://www40.statcan.ca/l01/cst01/demo02.htm (Accessed 17 November 2005)
   Google Scholar
• Rehm J, Frick U, Hartwig C, Gutzwiller F, Gschwend P, Uchtenhagen A. Mortality in heroin-assisted treatment in Switzerland 1994 – 2000. Drug Alcohol Depend 2005; 79: 137–143
   PubMed Web of Science ®Google Scholar
• Ramirez-Jonville A. Toxicomanies: la politique de reduction des risques en France et en Espagne. [Drug addiction: harm reduction policies in France and Spain]. Presse Med 2006; 35: 1151–1161
   PubMedGoogle Scholar